Angioplasty

Outlook on the Balloon Catheters Global Market to 2026 - Increasing Rate of Cardiovascular Diseases is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 7, 2021
Health, Medical Devices, Cardiology

The market is expected to surge in the coming years, due to the rising cases of cardiovascular diseases, worldwide.

Key Points: 
  • The market is expected to surge in the coming years, due to the rising cases of cardiovascular diseases, worldwide.
  • According to the World Health Organisation, an estimated number of 17.9 million people had died from cardiovascular diseases in the year 2019.
  • In the current market, there has been a rise in the trend of transcatheter aortic valve replacement, and balloon aortic valvuloplasty.
  • Balloon catheters are widely expected to be used in the older population, which would have a positive impact on the market.

First Patients in Canada Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

Retrieved on: 
Monday, August 30, 2021
Research, Medical Devices, Surgery, Medical Supplies, Clinical Trials, Cardiology, Other Health, Biotechnology, Health, Science, Degenerative disease, Calcium, Toronto General Hospital, SEC, Efficiency, Hospital, Plaque, Risk, OAS, Angioplasty, Woman, Form 10-K, Center, Diabetes, Atherosclerosis, CE, Artery, Man, Diamondback, Death, Heart, Thrombus, Sale, PCI, Technology, MD, Contraindication, USA, University Health Network, Twitter, Form 10-Q, Testosterone and the cardiovascular system, Moyamoya disease, Mark (given name), Toronto, NASDAQ, PTCA, Korea Disease Control and Prevention Agency, De novo, Organization, FDA, COAST, CAD, Coronary artery disease, Cardiovascular disease, Private Securities Litigation Reform Act, Annual report, CSI, Interventional cardiology, EF, Physician, Leg, News, Patient, MACE, Dissection, COVID-19, Pharmaceutical industry, Medical imaging, Coronary Artery Disease (CAD), Cardiovascular Systems, Inc., CORONARY ARTERY DISEASE (CAD), CARDIOVASCULAR SYSTEMS, INC.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360Coronary Orbital Atherectomy System (OAS).

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360Coronary Orbital Atherectomy System (OAS).
  • Dr. Kalra said, Patients with calcific coronary artery disease can have poor clinical outcomes unless optimally treated.
  • Scott Ward, Chairman, President and Chief Executive Officer of CSI, said, We are excited to announce the first commercial use of the Diamondback 360 Coronary OAS in Canada.
  • Indications: The Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a percutaneous orbital atherectomy system indicated to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for PTCA or stenting due to de novo, severely calcified coronary artery lesions.

Global Laser Processing Market to Reach $15.9 Billion by 2024

Retrieved on: 
Wednesday, August 11, 2021
LASER, Intelligence, Industry, Welding, Internet, Defense, Health, Forecasting, CAGR, Medicine, Geography, Photon, Coherent, Inc., Semiconductor, List of life sciences, GIA, COVID-19, Stimulated emission, Research, Angioplasty, US, Light, Electromagnetic radiation, Players, SAN, Laser, Marketing, Growth, 3D printing

SAN FRANCISCO, Aug. 11, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Laser Processing - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Aug. 11, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Laser Processing - Global Market Trajectory & Analytics" .
  • Laser cutting, laser welding, hybrid laser welding, laser marking, laser drilling, laser cladding, laser brazing, and laser cleaning are among the various types of laser processes.
  • Amid the COVID-19 crisis, the global market for Laser Processing is projected to reach US$15.9 Billion by 2024, registering a compounded annual growth rate (CAGR) of 7.6% over the analysis period.
  • China represents the largest regional market for Laser Processing, accounting for an estimated 24.9% share of the global total.

American Medical Association Issues New Category III CPT Code for ZOLL Medical’s TherOx SSO2 Therapy

Retrieved on: 
Monday, August 9, 2021
Medical Devices, Health, Technology, Other Technology, Manufacturing, Other Manufacturing, American Medical Association, Data management, Leadership, AMA, FDA, Asahi Kasei, Indian Medical Association, Mortality, Muscle tissue, Infarction, CPT, Ventilation, Temperature, ACC, EMS, Life, Multimedia, Category, Review, Solution, Patient, Dialysis, Society, Physician, CPR, American College, STEMI, Angioplasty, Angiography, Ammonia, LAD, SCAI, Health care, Hospital, Fluoroscopy, Medicare, WW, Hamad Medical Corporation, Medical device, 3D printing, Pharmaceutical industry, ZOLL Medical Corporation, Asahi Kasei, ZOLL MEDICAL CORPORATION, ASAHI KASEI

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the American Medical Association (AMA) CPT Editorial Panel issued a new Category III CPT code, effective July 1, 2021, for its TherOx SuperSaturated Oxygen (SSO2) Therapy.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the American Medical Association (AMA) CPT Editorial Panel issued a new Category III CPT code, effective July 1, 2021, for its TherOx SuperSaturated Oxygen (SSO2) Therapy.
  • View the full release here: https://www.businesswire.com/news/home/20210809005114/en/
    The American Medical Association has issued CPT code 0659T for ZOLLs TherOx System, which delivers SSO2 Therapy immediately post-PCI to reduce infarct size.
  • Multiple clinical trials have demonstrated the efficacy of SSO2 Therapy to reduce infarct size.1,2,3
    The Category III CPT code for SSO2 Therapy was supported by the leadership of the Society for Cardiac Angiography and Interventions (SCAI) and the American College of Cardiology (ACC).
  • SSO2 Therapy was developed by Irvine, California-based TherOx, Inc., now part of ZOLL Medical Corporation.

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

Retrieved on: 
Friday, July 23, 2021
Medical specialties, Medicine, Clinical medicine, Vascular diseases, Neurosurgery, Vascular surgery, Carotid stenting, Interventional radiology, Carotid artery stenosis, Stent, Restenosis, Angioplasty

The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device .

Key Points: 
  • The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device .
  • These are the first of 315 patients who are expected to be enrolled in the trial and treated with CGuard EPS in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting.
  • I believe that the initiation of this trial marks an important milestone for the potential approval of CGuard EPS and the potential of CGuard EPS in advancing the treatment of CAD and stroke prevention, commented Dr. Metzger.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Philips announces first patient enrollment in DEFINE GPS global multicenter study to assess superiority of PCI procedures guided by co-registered iFR and interventional angiography

Retrieved on: 
Tuesday, June 22, 2021
Medicine, Clinical medicine, Cardiovascular system, Interventional cardiology, Medical devices, Percutaneous coronary intervention, Angioplasty, Coronary stent, Cardiology, Drug-eluting stent, Instantaneous wave-free ratio

DEFINE GPS is a follow-up to the DEFINE PCI study [1] a one-year trial sponsored by Philips that evaluated the potential of treating residual ischemia in order to improve clinical outcomes for coronary stent patients.

Key Points: 
  • DEFINE GPS is a follow-up to the DEFINE PCI study [1] a one-year trial sponsored by Philips that evaluated the potential of treating residual ischemia in order to improve clinical outcomes for coronary stent patients.
  • With DEFINE GPS we will be able to definitively determine if a physiology-based PCI approach results in superior patient outcomes compared to standard angioplasty.
  • The DEFINE GPS study is sponsored by Philips, with the Cardiovascular Research Foundation overseeing core lab and clinical event committee activities.
  • The DEFINE PCI Trial: Blinded Physiological Assessment of Residual Ischemia after Successful Angiographic Percutaneous Coronary Intervention, presented at ACC 2019.

Sectoral Asset Management Makes $9M Investment into Cagent Vascular

Retrieved on: 
Thursday, June 17, 2021
Cardiology, Medical Supplies, Surgery, Health, Medical devices, Hospitals, Technology, Other Technology, Manufactured goods, Angioplasty, Interventional radiology, Balloon catheter, Balloon, Catheter, Serration

Cagent Vascular Inc.1, a developer of next generation angioplasty balloons using proprietary serration technology, announced the investment of $9M by Sectoral Asset Management.

Key Points: 
  • Cagent Vascular Inc.1, a developer of next generation angioplasty balloons using proprietary serration technology, announced the investment of $9M by Sectoral Asset Management.
  • The Serranator PTA Serration Balloon Catheter is an angioplasty device with serrated metal strips embedded on a semi-compliant balloon.
  • Marc-Andre Marcotte, of Sectoral added, We have been very impressed by Cagents achievements thus far and are excited to partner with them.
  • The information contained herein obtained from Cagent Vascular management is believed to be reliable.

Global Neurovascular Devices/Interventional Neurology Market (2021 to 2026) - Rise in Demand for Minimally Invasive Neurosurgical Procedures Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Surgery, Health, Medical devices, Interventional radiology, Medicine, Medical specialties, Clinical medicine, Interventional Neuroradiology, Embolization, Angiography, Thrombectomy, Stent, Angioplasty

The neurovascular devices/ interventional neurology market size is expected to grow from an estimated USD 2.5 billion in 2021 to USD 3.8 billion by 2026, at a CAGR of 8.6%.

Key Points: 
  • The neurovascular devices/ interventional neurology market size is expected to grow from an estimated USD 2.5 billion in 2021 to USD 3.8 billion by 2026, at a CAGR of 8.6%.
  • On the basis of product, the neurovascular devices/interventional neurology market is segmented into aneurysm coiling & embolization devices, cerebral balloon angioplasty & stenting systems, support devices, and neuro thrombectomy devices.
  • Based on end-user, the neurovascular devices/interventional neurology market has been segmented into hospitals & surgical centers, ambulatory care centers, and research laboratories, and academic institutes.
  • North America accounted for the largest market share in the neurovascular devices/interventional neurology market in 2020.

Two-year data from the TOBA II BTK clinical trial demonstrate durability of dissection repair below the knee with the Philips Tack Endovascular System

Retrieved on: 
Thursday, June 3, 2021
Medicine, Clinical medicine, Health sciences, Bruton's tyrosine kinase, Angioplasty, TIMI, Clinical trial, Revascularization, Osteochondritis dissecans

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial.

Key Points: 
  • Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial.
  • Across all patients in the TOBA II BTK clinical trial at two years, 73.6% had freedom from clinically driven target lesion revascularization (CD-TLR) and did not require a repeat procedure for the treated artery segment.
  • These positive two-year data reiterate the clinical importance of below-the-knee dissection repair and validates the sustained durability of Tack-optimized interventions.
  • The two-year TOBA II BTK data also show sustained improvement in patients quality of life.

Cardiovascular Systems, Inc. Reports Fiscal 2021 Third-Quarter Financial Results

Retrieved on: 
Thursday, May 6, 2021
Health, Surgery, Cardiology, Medical devices, Interventional radiology, Medical specialties, Medicine, Clinical medicine, Medical devices, Angioplasty, Stent, Artery, Peripheral Artery Disease (PAD), Coronary Artery Disease (CAD), Cardiovascular Systems, Inc., PERIPHERAL ARTERY DISEASE (PAD), CORONARY ARTERY DISEASE (CAD), CARDIOVASCULAR SYSTEMS, INC.

Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation.

Key Points: 
  • Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation.
  • These systems use a diamond-coated crown, attached to an orbiting shaft, which sands away plaque while preserving healthy vessel tissue \xe2\x80\x94 a critical factor in preventing reoccurrences.
  • Balloon angioplasty and stents have significant shortcomings in treating hard, calcified lesions.
  • CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart.